Welcome to our dedicated page for JUPITER NEUROSCIENCES SEC filings (Ticker: JUNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a biotech filing packed with pharmacokinetic charts and clinical risk factors is hard enough; add Jupiter Neurosciences’ focus on neuro-inflammation chemistry and the pages multiply quickly. If you have ever searched for “Jupiter Neurosciences SEC filings explained simply”, you already know the challenge. Our platform removes the guesswork and delivers a Jupiter Neurosciences annual report 10-K simplified—complete with plain-English explanations of JOTROL research milestones, cash runway metrics, and FDA-related risk disclosures.
Stock Titan’s AI models scan every line the instant it hits EDGAR, whether it is a Jupiter Neurosciences quarterly earnings report 10-Q filing, an 8-K disclosing interim trial data, or a Jupiter Neurosciences Form 4 insider transactions real-time alert. Need to monitor “Jupiter Neurosciences executive stock transactions Form 4” before the market reacts or understand a sudden “Jupiter Neurosciences 8-K material events explained”? Our AI highlights the who, what, and why, then links directly to the original document for audit-ready transparency.
Investors use these insights to track R&D expense trends, anticipate dilution, and benchmark progress against peer pipelines. Want an at-a-glance view of insider confidence? The dedicated dashboard surfaces every “Jupiter Neurosciences insider trading Form 4 transactions” with context. Curious about governance? Drill into the “Jupiter Neurosciences proxy statement executive compensation” section to see how option grants align with trial milestones. From “Jupiter Neurosciences earnings report filing analysis” to understanding Jupiter Neurosciences SEC documents with AI, the information you need is distilled, summarized, and ready for immediate action—no PhD in medicinal chemistry required.
Jupiter Neurosciences (JUNS) Form 4 filing: President, Chief Business Officer and Director Alison D. Silva reported three open-market purchases on 01 July 2025 totaling 750 common shares at an average price of roughly $1.03 per share. Following the transactions, Silva directly owns 112,777 shares of JUNS common stock. No derivative security activity was disclosed.
The transactions are coded “P,” indicating routine open-market buys and not part of a Rule 10b5-1 trading plan. While the dollar value is modest (≈ $770), insider buying is generally interpreted as a vote of confidence in the company’s prospects. However, the size of the purchase is immaterial to overall share count and does not meaningfully affect ownership structure.
Income Opportunity Realty Investors, Inc. (IOR) – Form 4 insider activity
Transcontinental Realty Investors, Inc., a 10% owner and director of IOR, disclosed six open-market purchases of the issuer’s common stock between 06/02/2025 and 06/23/2025. Each trade was executed at a consistent price of $17.90 per share.
- Total shares purchased: 184.
- Aggregate cash outlay: $3,293.60 (184 × $17.90).
- Post-transaction beneficial ownership: 3,435,406 shares, held directly.
The incremental purchases increased the reporting person’s stake by approximately 0.005% relative to its disclosed holding at the start of the period, suggesting the transactions were signal-oriented rather than intended to materially alter ownership. No derivative securities were reported, and all transactions were classified under code “P” for open-market purchases. The filing was signed by Erik L. Johnson, President & CEO of Transcontinental Realty Investors, on 07/03/2025.
Because the volume is immaterial compared with the owner’s existing 3.4 million-share position, the market impact is expected to be limited; however, continued buying by a control shareholder can be viewed positively as it indicates ongoing confidence in IOR’s equity at the stated price level.
General Mills, Inc. (GIS) – Form 4 insider transaction
Chief Supply Chain Officer Paul J. Gallagher reported two automatic transactions on 28 and 29 June 2025 tied to the vesting of equity awards. A total of 3,509 common shares were withheld at $50.52 per share under transaction code “F” to satisfy tax-withholding obligations, not discretionary selling. After the withholding, Gallagher directly owns 44,549.9002 shares and indirectly holds 323.18 shares through the General Mills Savings Plan. Because the activity was non-open-market and represents less than 0.01% of shares outstanding, it is considered routine with limited impact on share supply or insider sentiment.
General Mills, Inc. (GIS) – Form 4 insider transaction
Chief Supply Chain Officer Paul J. Gallagher reported two automatic transactions on 28 and 29 June 2025 tied to the vesting of equity awards. A total of 3,509 common shares were withheld at $50.52 per share under transaction code “F” to satisfy tax-withholding obligations, not discretionary selling. After the withholding, Gallagher directly owns 44,549.9002 shares and indirectly holds 323.18 shares through the General Mills Savings Plan. Because the activity was non-open-market and represents less than 0.01% of shares outstanding, it is considered routine with limited impact on share supply or insider sentiment.
FAQ
What is the current stock price of JUPITER NEUROSCIENCES (JUNS)?
What is the market cap of JUPITER NEUROSCIENCES (JUNS)?
What is the primary focus of Jupiter Neurosciences Inc?
How does the company generate revenue?
What therapeutic areas does Jupiter Neurosciences target?
What is JOTROL and its significance?
How does Jupiter Neurosciences differentiate itself from competitors?
What are the primary challenges faced by the company?
